Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study

References

• Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 2002;17:1136–42
   Google Scholar
• Matteoni CA, Younossi ZM, Gramlich T, et al. Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116 1413–9
   PubMed Web of Science ®Google Scholar
• Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003;108:1541–5
   PubMed Web of Science ®Google Scholar
• Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of non-alcoholic fatty liver disease to insulin resistance. Am J Med 1999;107:450–5
   Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. J Am Med Assoc 2001;285:2486–97
   Google Scholar
• Brea A, Mosquera D, Martin E, et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 2005;25:1045–50
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 2005;54:1065–74
   PubMed Web of Science ®Google Scholar
• Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986;292:13–5
   PubMed Web of Science ®Google Scholar
• Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745–50
   PubMed Web of Science ®Google Scholar
• Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005;16:421–7
   PubMed Web of Science ®Google Scholar
• Adams LA, Lindor KD. Treatment of hyperlipidemia in nonalcoholic fatty liver disease: fat for thought. Indian J Gastroenterol 2004;23:127–8
   PubMedGoogle Scholar
• Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343–51
   PubMed Web of Science ®Google Scholar
• Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103–7
   PubMed Web of Science ®Google Scholar
• Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004;39:1647–54
   Google Scholar
• Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413–9
   PubMed Web of Science ®Google Scholar
• Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2002;25: 1033–41
   Google Scholar
• Didangelos TP, Thanopoulou AK, Bousboulas SH, et al. The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. Curr Med Res Opin 2004;20:1393–401
   PubMed Web of Science ®Google Scholar
• Hatzitolios A, Savopoulos C, Lazaraki G, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004;23:131–4
   PubMedGoogle Scholar
• Harrison SA, Fincke C, Helinski D, et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004;20:623–8
   PubMed Web of Science ®Google Scholar
• Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537–44
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082–90
   PubMed Web of Science ®Google Scholar
• Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188–96
   PubMed Web of Science ®Google Scholar
• Donati G, Stagni B, Piscaglia F, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004;53:1020–3
   PubMed Web of Science ®Google Scholar
• Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40:1222–5
   PubMed Web of Science ®Google Scholar
• Kiyici M, Gulten M, Gurel S, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003;17:713–8
   PubMed Web of Science ®Google Scholar
• Funatsu T, Goto M, Kakuta H, et al. Reduction in hepatic nonesterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats. Biochim Biophys Acta 2002;1580:161–70
   PubMed Web of Science ®Google Scholar
• Isusi E, Aspichueta P, Liza M, et al. Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes. Atherosclerosis 2000;153:283–94
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001;3:83–92
   PubMedGoogle Scholar
• Ganotakis E, Tsimihodimos V, Bairaktari E, et al. Effects of various fibrates on serum alkaline phosphatase activity. Atherosclerosis 2002;165:187–8
   PubMed Web of Science ®Google Scholar
• Athyros VG, Elisaf M, Papageorgiou AA, et al; GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease. A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Am J Kidney Dis 2004;43:589–99
   Google Scholar
• Elisaf M, Tsimichodimos V, Bairaktari E, Siamopoulos KC. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cardiovasc Pharmacol 1999;34:60–3
   PubMed Web of Science ®Google Scholar
• Carnethon MR, Fortmann SP, Palaniappan L, et al. Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987–1998. Am J Epidemiol 2003;158:1058–67
   PubMed Web of Science ®Google Scholar
• Tang W, Miller MB, Rich SS, et al; Linkage analysis of a composite factor for the multiple metabolic syndrome: the National Heart, Lung, and Blood Institute Family Heart Study. Diabetes 2003;52:2840–7
   PubMed Web of Science ®Google Scholar
• Lonardo A, Loria P, Leonardi F, et al; POLI.ST.E.N.A. Study Group. Policentrica Steatosi Epatica Non Alcolica. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Dig Liver Dis 2002;34:204–11
   Google Scholar
• Hak AE, Pols HA, Stehouwer CD, et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinol Metab 2001;86:4398–05
   PubMed Web of Science ®Google Scholar
• Park SH, Kim BI, Yun JW, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 2004;19:694–8
   PubMed Web of Science ®Google Scholar
• Kerner A, Avizohar O, Sella R, et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005;25:193–7
   PubMed Web of Science ®Google Scholar
• de Maat MP, Trion A. C-reactive protein as a risk factor versus risk marker. Curr Opin Lipidol 2004;15:651–7
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al.; for the METS-Greece Collaborative Group. Prevalence of atherosclerotic cardiovascular disease among subjects with the metabolic syndrome with or without diabetes mellitus. Curr Med Res Opin 2004;20:1691–701
   Google Scholar
• Bilz S, Wagner S, Schmitz M, et al. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res 2004;45:174–85
   PubMed Web of Science ®Google Scholar
• Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004;174:193–6
   Google Scholar
• Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003;108:426–31
   PubMed Web of Science ®Google Scholar
• Videla LA, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med 2004;37:1499–507
   PubMed Web of Science ®Google Scholar
• Diehl AM. Fatty liver, hypertension, and the metabolic syndrome. Gut 2004;53:923–4
   PubMed Web of Science ®Google Scholar
• Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917–23
   PubMed Web of Science ®Google Scholar
• Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287–92
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Nikas S, Hatzidimou K, et al. Lipid-lowering drugs and serum liver enzymes: the effects of body weight and baseline enzyme levels. Fund Clin Pharmacol 2003;17:491–4
   PubMed Web of Science ®Google Scholar
• Sorrentino P, Tarantino G, Conca P, et al. Silent non-alcoholic fatty liver disease: a clinical-histological study. J Hepatol 2004;41:751–7
   PubMed Web of Science ®Google Scholar
• Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387–95
   PubMed Web of Science ®Google Scholar
• Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabetic Med 2005;22:1141–5
   PubMed Web of Science ®Google Scholar
• Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997;42:1428–32
   Google Scholar
• Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci 1995;40:2002–9
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Scala L, et al. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabetic Med 2005;22: 1354–8
   PubMed Web of Science ®Google Scholar
• Suzuki A, Lindor K, St Saver J, et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005;43:1060–6
   PubMed Web of Science ®Google Scholar
• Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722–8
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 2005;6:283–96
   Google Scholar
• Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005;54:3541–6
   PubMed Web of Science ®Google Scholar